Long-term Safety in Epstein-Barr Virus-Seropositive Kidney-only Transplant Recipients Treated With Belatacept in Clinical Practice: Final Study Results From the ENLiST Registry

By sjmartinez • May 21, 2024

Larsen CP, Vincenti F, D Kou T, Shadur CA, Bresnahan B, Jordan SC, Woodle ES, Goes N, Vella J, Wojciechowski D, Polinsky MS, Gomez-Caminero A. Long-term Safety in Epstein-Barr Virus-Seropositive Kidney-only Transplant Recipients Treated With Belatacept in Clinical Practice: Final Study Results From the ENLiST Registry. Transplant Direct. 2024 May 17;10(6):e1644. doi: 10.1097/TXD.0000000000001644. PMID: 38769981; PMCID: PMC11104716.

Tags: Cedars Sinai DoM, Nephrology, Publications

Related Posts

A CD57+ CD8 T cell subset links cytotoxic T cell cytotoxicity to fibrotic lung disease in systemic sclerosis

Sasaki T, Cao Y, Sowerby JM, Higashioka K, Marks KE, Elahee M, Kamiya M, Dellaripa PF, Ainsworth RI, Taylor KE, Bottini N, Wolters P, Kim[...]

Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design

Plutzky J, Taub PR, Bhatt DL, Al Dhaybi O, Aroda VR, Basile JN, Bloch MJ, Budoff M, Busch RS, Buse JB, Cheung D, Christofides EA,[...]

Corrigendum to “Deep learning in fetal, infant, and toddler neuroimaging research”[Dev. Cognit. Neurosci. (2026), 101680]

Chin JH, Wyburd MK, Ayzenberg V, Bayet L, Bilgic B, Chen EM, Chen Y, Dineen Á, Fujita S, Liu J, Jun Y, Camacho MC, Zöllei[...]